Chinese Peptide Company: API Triptorelin Acetate Has Passed the GMP Inspection Conducted by Zhejiang Medical Products Administration

Announcement of GMP inspection results of Zhejiang Medical Products Administration (No.1 in 2020)：According to the 《Law of the People’s Republic of China on the Administration of Drugs》（Amended in 2019）and the requirements the implementation of 《Pharmaceutical Administration Law of the People’s Republic of China》(No. 103 of 2019) conducted by National Medical Products Administration, after on-site inspection, API drug (Triptorelin Acetate) of Chinese Peptide Company met the requirements of 《Good Manufacturing Practice for Drugs 》(Amended in 2010).